Anti-dsDNA Response After Pulse Cyclophosphamide Therapy, with Early Proteinuria Trend as a Secondary Finding
Annals of International Medical and Dental Research · 2026-08 · 12 (4) · 29-35
DOI: 10.53339/aimdr.2026.12.4.5 ↗Abstract
Background: Lupus nephritis is a major renal manifestation of systemic lupus erythematosus and requires close monitoring of immunological and urinary response after induction therapy. Anti-dsDNA level and proteinuria are commonly used markers of disease activity and treatment response in routine clinical practice. Objective: To assess anti-dsDNA response after pulse cyclophosphamide therapy among patients with lupus nephritis, with early proteinuria trend as a secondary finding. Methods: This retrospective observational study was conducted at Khwaja Yunus Ali Medical College & Hospital from July to December 2025 among 34 patients with lupus nephritis or SLE-related renal syndrome receiving pulse cyclophosphamide therapy. Clinical features, anti-dsDNA levels, and proteinuria grades were analyzed. Data were expressed as frequency, percentage, median, and interquartile range, with paired non-parametric tests used for analysis. A P-value
EUVIMED